Stryker price target raised to $345 from $330 at Truist

Truist raised the firm’s price target on Stryker to $345 from $330 and keeps a Hold rating on the shares. The company reported a “solid” Q4 earnings beat and its top-line growth is one of the best in large cap MedTech, the analyst tells investors in a research note, adding that the firm expects it to continue outperforming. Truist is also raising its FY24 EPS view by 32c to $11.84, noting that Stryker’s faster revenue growth should put the company in a better position to deliver on margins.